Surgical treatment of clinically early-stage endometrial carcinoma without systematic lymphadenectomy

Revista da Associacao Medica Brasileira

Volumn 60, Issue 6, 2014, Pages 571-576

  Bezerra, Artur Lício Rocha ^a   Batista, Thales Paulo ^a,b   Martins, Mário Rino ^b   Carneiro, Vandré Cabral Gomes ^a,b  

^a INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^b Hospital do Câncer de Pernambuco   (Brazil)

Author keywords

Endometrial neoplasms; Lymph node dissection; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EARLY CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MORBIDITY; PATIENT CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; SALPINGOOOPHORECTOMY; WOUND DEHISCENCE; CARCINOMA; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; MORTALITY; OVARIECTOMY; PROCEDURES; RECURRENT DISEASE; SALPINGECTOMY; SURVIVAL; TREATMENT OUTCOME;

AGED; CARCINOMA; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; MIDDLE AGED; NEOPLASM STAGING; OVARIECTOMY; RADIOTHERAPY, ADJUVANT; RECURRENCE; SALPINGECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937733030     PISSN: 01044230     EISSN: 18069282     Source Type: Journal    
DOI: 10.1590/1806-9282.60.06.017     Document Type: Article

References (18)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon: International Agency for Research on Cancer; 2013. [cited 2014 mar 10]. Available from:globocan.iarc.fr.
2. Brazilian Ministry of Health. Estimation 2014: Cancer incidence in Brazil. Rio de Janeiro: National Cancer Institute (INCA); 2014. [cited 2014 mar 10]. Available from:http://www.inca.gov.br/estimativa/2014/.
3. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet.2000;70(2):209-62.
4. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam- Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404-11.
5. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet. 2009;373(9658):125-36.
6. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16.
7. Uccella S, Podratz KC, Aletti GD, Mariani A. Re: Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2009;101(12):897- 8; author reply 898-9.
8. Creasman WT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid Gynecol Oncol. 2010;116(3):293-4.
9. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): A retrospective cohort analysis. Lancet. 2010;375(9721):1165-72.
10. Dowdy SC, Mariani A. Lymphadenectomy in endometrial cancer: when, not if. Lancet. 2010;375(9721):1138-40.
11. Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS. The outcomes of 27, 063 women with unstaged endometrioid uterine cancer. Gynecol Oncol. 2007;106(2):282-8.
12. Barbosa CP, Moscovitz T, Martins NV, Souza AMB, Soubhia IT, Aldrighi APS. [Laparascopic approach to endometrial cancer]. Rev Bras Ginecol Obstet. 1999;21(1):41-5.
13. Kang S, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, et al. How low is low enough Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: A Korean multicenter study. J Gynecol Oncol. 2012;23(4):251-6.
14. Kang S, Kang WD, Chung HH, Jeong DH, Seo SS, Lee JM, et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: A Korean gynecologic oncology group study. J Clin Oncol. 2012;30(12):1329-34.
15. Alhilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer. Gynecol Oncol. 2013;13(1):103-8.
16. Vaizoglu F, Yuce K, Salman MC, Basaran D, Calis P, Ozgul N, et al. Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer. Arch Gynecol Obstet. 2013;288(6):1391-7.
17. Zhang C, Wang C, Feng W. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer. 2012;22(8):1373-7.
18. Clements AE, Tierney BJ, Cohn DE, Straughn JM Jr. Is selective lymphadenectomy more cost-effective than routine lymphadenectomy in patients with endometrial cancer Gynecol Oncol. 2013;128(2):166-70.